BIOCHEMICAL SOCIETY TRANSACTIONS oxygenator containing 30p~-cytochalasin Band returned to the control oxygenator, and a further influx of glucose determined 4min later. The glucose concentration in both oxygenators was the same. The results (Table 2) show that the inhibition is completely reversed within 4min of perfusing the brain with cytochalasin-free blood. The rapid reversibility of the inhibition is in agreement with studies of effects of cytochalasin B on hexose transport in other cell systems (Zigmond & Hirsch, 1972; Czech et al., 1973 Hypoglycin (L-2-amino-3-methylenecyclopropylpropionic acid) is the toxic hypoglycaemic principle of the Jamaican ackee fruit, Blighia sapida (Sherratt et al., 1971) and is converted in vivo into methylenecyclopropylacetyl-CoA (von Holt, 1966) . This metabolite inhibits Boxidation in isolated mitochondria at the stage catalysed by butyryl-CoA dehydrogenase (EC 1.3.99.2), resulting in the incomplete oxidation of straight-chain fatty acids with butyrate as the main end product (Osmundsen & Sherratt, 1975a,b) . Inhibition of fatty acid oxidation in vivo by metabolites of hypoglycin is thought to cause hypoglycaemia indirectly Senior et al., 1975) . Hypoglycin, or a metabolite (most probably methylenecyclopropylacetyl-CoA), also interferes with the catabolism of leucine and isoleucine at the stage of dehydrogenation of isovaleryl-CoA and of 2-methylbutyryl-CoA, causing greatly increased plasma concentrations of isovalerate and 2-methylbutyrate respectively (Tanaka et al., 1972) . Smaller amounts of butyrate were also found (Tanaka et af., 1972). Here we confirm these observations and report more detailed studies on the changes in the concentrations of some volatile fatty acids in plasma after administration of hypoglycin, and we also show that hexanoate and propionate accumulate. Further, increased concentrations of all these compounds are associated with inhibition of some acyl-CoA dehydrogenases in vivo.
Hypoglycin (L-2-amino-3-methylenecyclopropylpropionic acid) is the toxic hypoglycaemic principle of the Jamaican ackee fruit, Blighia sapida (Sherratt et al., 1971) and is converted in vivo into methylenecyclopropylacetyl-CoA (von Holt, 1966) . This metabolite inhibits Boxidation in isolated mitochondria at the stage catalysed by butyryl-CoA dehydrogenase (EC 1.3.99.2), resulting in the incomplete oxidation of straight-chain fatty acids with butyrate as the main end product (Osmundsen & Sherratt, 1975a,b) . Inhibition of fatty acid oxidation in vivo by metabolites of hypoglycin is thought to cause hypoglycaemia indirectly Senior et al., 1975) . Hypoglycin, or a metabolite (most probably methylenecyclopropylacetyl-CoA), also interferes with the catabolism of leucine and isoleucine at the stage of dehydrogenation of isovaleryl-CoA and of 2-methylbutyryl-CoA, causing greatly increased plasma concentrations of isovalerate and 2-methylbutyrate respectively (Tanaka et al., 1972) . Smaller amounts of butyrate were also found (Tanaka et af., 1972) . Here we confirm these observations and report more detailed studies on the changes in the concentrations of some volatile fatty acids in plasma after administration of hypoglycin, and we also show that hexanoate and propionate accumulate. Further, increased concentrations of all these compounds are associated with inhibition of some acyl-CoA dehydrogenases in vivo.
Butyryl-CoA and isovaleryl-CoA dehydrogenase activities, in extracts of mitochondria isolated from livers taken from rats 24h after administration of hypoglycin, were low or 560th MEETING, OXFORD Table 1 . Acyl-CoA akhydrogenase activities and the rate ofpalmitoylcarnitine oxidation in mitochondria isolated from livers taken from rats after administration of hypoglycin Acyl-CoA dehydrogenase activities in sonicated mitochondria were measured spectrophotometrically at 20°C . The ADP-stimulated rate of palmitoylcarnitine oxidation in intact mitochondria in the presence of 10mM-malonate was measured polarographically at 30°C (Osmundsen & Sherratt, 1975a) (2) absent when compared with the controls (Table 1 ). The ADP-stimulated rate of oxidation of palmitoylcarnitine to acetoacetate was impaired by 30-60 % in these mitochondria (Table 1 ). The oxygen consumed during the oxidation of palmitoylcarnitine was only about 85 %of the theoretical value, suggesting that /3-oxidation in vivo is incomplete after injection of hypoglycin. This could explain the accumulation of butyrate and hexanoate after deacylation of their CoA esters, which cannot be oxidized completely because of inhibition of butyryl-CoA dehydrogenase (see . After 48 h no inhibitions were found and restoration of enzyme activity in uivo coincided with the disappearance of short-chain fatty acids from the plasma (Fig. 1) . The combined concentrations of isovalerate and 2-methylbutyrate (these compounds cannot be separated by g.1.c.) reached a peak at 4 m~, whereas those of butyrate and of hexanoate reached peaks at 0 . 3 m~ and 0.1 mM respectively. Propionate, which was only detected several hours after injection of hypoglycin, reach a peak concentration of 0 . 3 m~ (Fig.   1 ). Isovalerate plus 2-methylbutyrate (1.7m~) and relatively high concentrations of butyrate (1.9m~) were also found in the plasma of albino Balb/c-mice 6h after administration of hypoglycin (500mg/kg body wt.) (S. S. Al-Bassam, unpublished work). Accumulation of isovalerate and of 2-methylbutyrate results from deacylation of their accumulated CoA esters. Tanaka et al. (1972) proposed that there is a separate isovalerylCoA dehydrogenase, distinct from butyryl-CoA dehydrogenase normally involved in &oxidation, which can also be inhibited by a metabolite of hypoglycin. Alternatively, Engel (1974) suggested that methylenecyclopropylacetyl-CoA could reversibly inhibit a single short-chain acyl-CoA dehydrogenase of broad specificity and that the pattern of inhibition could be explained in terms of different affinities of the enzyme for the various reactants. However, Osmundsen et al. (1974) reported a partial separation of isovalerylCoA dehydrogenase from butyryl-CoA dehydrogenase in rat liver, and that isovalerylCoA was not a substrate for purified ox liver butyryl-CoA dehydrogenase. The different time-courses of accumulation of butyrate and of isovalerate (Fig. 1) are further evidence for the existence of at least two acyl-CoA dehydrogenases with different specificities. The fact that isobutyrate, which could result from a block in the catabolism of valine, was not detected suggests that there is also a separate isobutyryl-CoA dehydrogenase which is not inhibited. The late appearance of propionate (Fig. 1) may be linked to disappearance of 2-methylbutyrate, since propionyl-CoA is a product of the oxidation of 2-methylbutyrate. In poisoned animals propionyl-CoA is presumably deacylated when its disposal by other pathways is impaired or rate-limiting. The possibility remains that some of the volatile fatty acids found in plasma may have been formed by microbial action in the lower intestine. Albino rats ( W g ) were starved for 24h and then injected intraperitoneally with hypoglycin (85 % pure, main contaminants leucine and isoleucine; 8OmgIkg body wt.). The animals were kept at an ambient temperature of 28°C to prevent them becoming hypothermic. Water was allowed, but food was withheld, during the experiment. Blood samples (0.5ml) were taken from the tail, and plasma was obtained by centrifugation. Glucose was determined by using glucose oxidase, and volatile fatty acids were extracted as described by Remsey & Denigne (1974) Methylenecyclopropylacetate (Fig. 1) is derived from deacylation of methylenecyclopropylacetyl-CoA. However, plasma concentrations fall dramatically before restoration of acyl-CoA dehydrogenase activities. Inhibition of butyryl-CoA dehydrogenase and isovaleryl-CoA dehydrogenase by methylenecyclopropylacetyl-CoA presumably involves very tight or irreversib!e binding of this metabolite since activity is not restored by prolonged dialysis. The protective effect of riboflavin against the chronic toxicity of hypoglycin (von Holt & von Holt, 1959) suggests that recovery from sub-lethal doses of hypoglycin involves synthesis de novo of these dehydrogenases which have flavin prosthetic groups.
VOl. 4 BIOCHEMICAL SOCIETY TRANSACTIONS
Familial type I1 hyperlipoproteinaemia is an autosomal dominant condition with incomplete penetrance, which is characterized clinically by xanthomatosis and premature atherosclerosis, and biochemically by increased concentrations of apparently normal plasma low-density lipoproteins (LD-lipoproteins). These lipoproteins form the main transport vehicle for plasma cholesterol, but cholesterol-balance studies in type I1 patients have failed to demonstrate that the condition derives from overproduction of cholesterol in these patients (Grundy & Ahrens, 1969; Lewis & Myant, 1967 ). An alternative possibility which has been investigated by a number of workers is that the abnormality may be a disorder of low-density lipoprotein apoprotein (apoLD-lipoprotein) metabolism.
Preliminary studies by Scott & Hurley (1969) and Hurley & Scott (1970) indicated that the half-life of labelled apoLD-lipoprotein in patients suffering from essential hypercholesterolaemia (which probably corresponds to Type I1 hyperlipoproteinaemia) was similar to that found in normal subjects. Conversely, Langer et al. (1972) noted a 52 % increase in the apoLD-lipoprotein half-life in heterozygous patients, associated with a normal absolute catabolic rate for the protein; in an investigation of the homozygous form of the condition, Simons et al. (1975) found that the mean half-life of the LD-lipoprotein was increased by 127 % over control values, whereas the absolute catabolic rate for the apoprotein also demonstrated an 84% increase. The discrepancies between these data are likely to derive from the use of different criteria in patient selection. In an attempt to resolve these discrepancies, we have reexamined the metaboIic handling of 1151-labelled LD-lipoprotein in four heterozygous type I1 hyperlipoproteinaemic patients and four control subjects.
The patients were members of a large family of clinically, genetically and biochemically proven type I1 hyperlipoproteinaemics, whereas the controls, matched for age and weight, were normal in these respects. All subjects ate a regular diet and were not receiving drug therapy known to influence plasma lipoprotein metabolism.
LD-lipoprotein was isolated from pooled plasma from healthy volunteers by agarosegel filtration (Rude1 et al., 1974) and ultracentrifugation, and radioiodinated with lZ5I
